blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3953378

EP3953378 - GENE THERAPIES FOR LYSOSOMAL DISORDERS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  02.02.2024
Database last updated on 28.09.2024
FormerRequest for examination was made
Status updated on  14.01.2022
FormerThe international publication has been made
Status updated on  16.10.2020
Formerunknown
Status updated on  16.05.2020
Most recent event   Tooltip03.05.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Prevail Therapeutics, Inc.
430 East 29th Street
Suite 940
New York, NY 10016 / US
[2022/07]
Inventor(s)01 / RHINN, Herve
430 East 29th Street, Suite 940
New York, New York 10016 / US
02 / ABELIOVICH, Asa
20 East 35th Street, Apt. 15E
New York, New York 10016 / US
03 / HECKMAN, Laura
430 East 29th Street, Suite 940
New York, New York 10016 / US
04 / HEFTI, Franz
20 East 74th Street, Apt. 14F
New York, New York 10021 / US
 [2022/07]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2022/07]
Application number, filing date20724264.510.04.2020
[2022/07]
WO2020US27788
Priority number, dateUS201962831840P10.04.2019         Original published format: US 201962831840 P
US202062990246P16.03.2020         Original published format: US 202062990246 P
[2022/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020210713
Date:15.10.2020
Language:EN
[2020/42]
Type: A1 Application with search report 
No.:EP3953378
Date:16.02.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 15.10.2020 takes the place of the publication of the European patent application.
[2022/07]
Search report(s)International search report - published on:EP15.10.2020
ClassificationIPC:C07K14/475, A61K48/00, C12N15/861
[2022/07]
CPC:
A61P25/28 (EP,IL,US); A61K35/761 (IL,US); A61K48/005 (EP,KR);
A61K38/162 (IL,US); A61K47/02 (EP,KR); A61K47/10 (EP,KR);
A61K48/0066 (EP,KR); A61K9/0019 (IL,US); A61K9/0085 (EP,IL,KR,US);
A61P25/16 (KR); A61P43/00 (EP,IL,KR,US); C07K14/47 (EP);
C12N15/86 (EP,IL,KR,US); C12N9/2402 (EP,KR); C12Y302/01045 (EP,IL,KR,US);
A01K2207/20 (EP); A01K2227/105 (EP); A01K2267/0306 (EP);
A61K38/00 (EP); C12N2750/14143 (EP,KR); C12N2800/22 (EP);
C12N2830/008 (EP); C12N2830/42 (EP); C12N2830/48 (EP);
C12N2830/50 (EP,KR); C12N2840/203 (EP,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/07]
TitleGerman:GENTHERAPIEN FÜR LYSOSOMALE ERKRANKUNGEN[2022/07]
English:GENE THERAPIES FOR LYSOSOMAL DISORDERS[2022/07]
French:THÉRAPIES GÉNIQUES POUR TROUBLES LYSOSOMAUX[2022/07]
Entry into regional phase04.11.2021National basic fee paid 
04.11.2021Designation fee(s) paid 
04.11.2021Examination fee paid 
Examination procedure04.11.2021Examination requested  [2022/07]
04.11.2021Date on which the examining division has become responsible
30.05.2022Amendment by applicant (claims and/or description)
01.02.2024Despatch of a communication from the examining division (Time limit: M04)
01.05.2024Reply to a communication from the examining division
Fees paidRenewal fee
20.04.2022Renewal fee patent year 03
20.04.2023Renewal fee patent year 04
15.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2012027558  (UNIV COLUMBIA [US], et al) [I] 11-20,25,27,28 * The query sequence SEQ ID NO:20 has 100 % identity (100 % similarity) over 23 positions in a common overlap (range (q:s): 23-1:1-23) with subject GSN:AZT83218 (length: 23) from WO2012027558-A2 published on 2012-03-01. *;
 [I]WO2014071282  (GENZYME CORP [US]) [I] 1-28 * examples 1-7 *;
 [I]WO2016179497  (SHIRE HUMAN GENETIC THERAPIES [US], et al) [I] 1-28 * examples 1-8; claims 1-44 *;
 [I]  - AGNIESZKA CIESIELSKA ET AL, "Cerebral Infusion of AAV9 Vector-encoding Non-self Proteins Can Elicit Cell-mediated Immune Responses", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (20130101), vol. 21, no. 1, doi:10.1038/mt.2012.167, ISSN 1525-0016, pages 158 - 166, XP055700835 [I] 1-28 * page 158 - page 166 *

DOI:   http://dx.doi.org/10.1038/mt.2012.167
 [I]  - LLUIS SAMARANCH ET AL, "AAV9-mediated Expression of a Non-self Protein in Nonhuman Primate Central Nervous System Triggers Widespread Neuroinflammation Driven by Antigen-presenting Cell Transduction", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (20140201), vol. 22, no. 2, doi:10.1038/mt.2013.266, ISSN 1525-0016, pages 329 - 337, XP055701101 [I] 1-28 * page 158 - page 166 *

DOI:   http://dx.doi.org/10.1038/mt.2013.266
 [A]  - Digitalcommons@unmc Digitalcommons@unmc ET AL, "Novel therapeutic approaches for Juvenile Neuronal Ceroid Novel therapeutic approaches for Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Lipofuscinosis (CLN3)", Part of the Medical Neurobiology Commons, (20170101), URL: https://digitalcommons.unmc.edu/cgi/viewcontent.cgi?article=1230&context=etd, XP055694551 [A] 1-28 * the whole document *
by applicantUS8945918
 WO2017184879
 US9879282
 WO2019070894
 WO2019070891
    - ALEXOPOULOU et al., BMC Cell Biol., (20080000), vol. 9, page 2
    - TOMOE et al., Gene, (20020000), vol. 297, no. 1-2, pages 21 - 32
    - MOKREJS et al., Nucleic Acids Res., (20060000), vol. 34, pages D125 - 30
    - LIU et al., Sci Rep., (20170000), vol. 7, page 2193
    - MCCARTY et al., Gene Ther., (20030000), vol. 10, no. 26, pages 2112 - 8
    - LING et al., JMol Genet Med, (20150000), vol. 9, page 3
    - WANG et al., JMol Biol, (19950000), vol. 250, no. 5, pages 573 - 80
    - FRANCOIS et al., J. Virol., (20050000), vol. 79, no. 17, pages 11082 - 11094
    - URABE et al., Hum Gene Ther, (20020000), vol. 13, no. 16, pages 1935 - 43
    - SMITH et al., Mol Ther, (20090000), vol. 17, no. 11, pages 1888 - 1896
    - ALBRIGHT et al., Mol Ther., (20180207), vol. 26, no. 2, pages 510 - 523
    - ROSARIO et al., Mol Ther Methods Clin Dev., (20160000), vol. 3, page 16026
    - SAMULSKI et al., J Virol., (19890000), vol. 63, no. 9, pages 3822 - 8
    - WRIGHT, Hum Gene Ther., (20090000), vol. 20, no. 7, pages 698 - 706
    - SVENNERHOLM et al., Clin Genet., (19860000), vol. 30, no. 2, pages 131 - 5
    - COX, Biologics, (20100000), vol. 4, pages 299 - 313
    - GOKER-ALPAN et al., JPediatr., (20030000), vol. 143, no. 2, pages 273 - 6
    - ROSHANSIDRANSKY, Diseases, (20170000), vol. 5, no. 1, page E10
    - GOKER-ALPAN et al., J Pediatr., (20030000), vol. 143, no. 2, pages 273 - 6
    - TYLKI-SZYMANSKA et al., J Inherit Metab Dis., (20100000), vol. 33, no. 4, pages 339 - 46
    - BIEGSTRAATEN et al., Brain, (20100000), vol. 133, no. 10, pages 2909 - 2919
    - HAKIMMATHIESON, Neurology, (19790000), vol. 29, no. 9, pages 1209 - 14
    - VANNUCCIVANNUCCI, Am JPhys Anthropol., (20190000), vol. 168, no. 2, pages 247 - 6 1
    - DEBINSKI et al., Expert Rev Neurother., (20090000), vol. 9, no. 10, pages 1519 - 27
    - MAZZULLI et al., Cell, (20110000), vol. 146, no. 1, pages 37 - 52
    - LIOU et al., J. Biol. Chem., (20060000), vol. 281, no. 7, pages 4242 - 4253
    - SUN et al., J. Lipid Res., (20050000), vol. 46, pages 2102 - 2113
    - FARFEL-BECKER et al., Dis. Model Mech., (20110000), vol. 4, no. 6, pages 746 - 752
    - VARDI et al., J Pathol., (20160000), vol. 239, no. 4, pages 496 - 509
    - GRABOWSKI et al., Ann. Intern. Med., (19950000), vol. 122, no. 1, pages 33 - 39
    - MANNING-BOG et al., Neurotoxicology, (20090000), vol. 30, no. 6, pages 1127 - 32
    - FARFEL-BECKER et al., Dis Model Mech., (20110000), vol. 4, no. 6, pages 746 - 52
    - ROCHA et al., AntioxidRedox Signal., (20150000), vol. 23, no. 6, pages 550 - 64
    - SUN et al., J Lipid Res., (20050000), vol. 46, no. 10, pages 2102 - 13
    - XU et al., Mol GenetMetab., (20110000), vol. 102, no. 4, pages 436 - 47
    - KUO et al., Hum Mol Genet., (20100000), vol. 19, no. 9, pages 1633 - 50
    - ROCKENSTEIN et al., Hum Mol Genet., (20160000), vol. 25, no. 13, pages 2645 - 60
    - PAPADOPOULOS et al., Hum Mol Genet., (20180000), vol. 27, no. 10, pages 1696 - 1710
    - HAMBYSOFRONIEW, Neurotherapeutics, (20100000), vol. 7, no. 4, pages 494 - 506
    - FARFEL-BECKER et al., Dis. ModelMech., (20110000), vol. 4, no. 6, pages 746 - 752
    - FARFEL-BECKER et al., Hum Mol Genet., (20110000), vol. 20, no. 7, pages 1375 - 86
    - BOOTH et al., Trends Neurosci., (20170000), vol. 40, no. 6, pages 358 - 70
    - MCMAHON et al., Mol GenetMetab., (20180000), vol. 123, no. 2, page S93
    - HINDERER et al., Mol Ther., (20140000), vol. 22, no. 12, pages 2018 - 27
    - HINDERER et al., Mol Ther Methods Clin Dev., (20140000), vol. 1, page 14051
    - HINDERER et al., Mol Ther., (20150000), vol. 23, no. 8, pages 1298 - 307
    - HINDERER et al., Mol Genet Metab., (20160000), vol. 119, no. 1-2, pages 124 - 30
    - BUTT et al., Toxicol Pathol., (20150000), vol. 43, pages 513 - 8
    - CHAMANZA et al., Toxicol Pathol., (20100000), vol. 38, no. 4, pages 642 - 57
    - SARDI et al., Proc NatlAcad Sci USA, (20110000), vol. 108, no. 29, pages 12101 - 6
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.